Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new way to deliver treatment using the ECAP-controlled closed-loop spinal cord stimulation SCS system called the Evoke System. This study focuses on patients who experience chronic pain in the trunk andor limbs. The goal is to test and assess new software and hardware features that may improve how the Evoke System delivers treatment. Participants will use the Evoke Spinal Cord Stimulation System, which measures electrical activity called evoked compound action potentials ECAPs. The device automatically adjusts the stimulation current to keep the ECAP amplitude consistent. This study involves a single group of participants using this novel device and will continue through to study completion, which may last up to two years. During the study, participants will be monitored for changes in ECAPs measured by the Evoke System. Researchers will evaluate these changes over the course of the study to understand how the device functions with the new features. Participants will need to provide informed consent and comply with study requirements while using the device. The total participation time can last up to two years, with regular assessments conducted throughout this period.
Actively Recruiting
This research aims to review anonymous medical records to study the clinical outcomes of various treatments for chronic pain. It is a retrospective, multi-center data review that includes multiple patient groups to evaluate different treatment approaches. The study focuses on patients who have been implanted with or are eligible for spinal cord stimulation systems or other treatments such as radiofrequency RF or intrathecal drug delivery systems IDS. The study compares different treatment methods, including Boston Scientific devices and non-Boston Scientific systems like spinal cord stimulation, RF, and IDS. It involves two groups patients eligible for these treatments and those who have received a prior treatment followed by a different chronic pain therapy. This evaluation uses de-identified data collected from medical charts without direct patient intervention. Participants involvement consists of reviewing their past medical data over approximately two years. Researchers will measure the responder rate, which indicates the effectiveness of the treatments through the study period. Since this is a data review, there are no active treatments or visits required, and patient privacy is maintained throughout the study.
Actively Recruiting
This research aims to gather real-world data on the outcomes of Boston Scientific neurostimulation systems used for pain management in everyday clinical practice. It focuses on evaluating the long-term effectiveness, economic value, and technical performance of these commercially approved neurostimulation devices when used according to their instructions. Participants will undergo a trial period with a Boston Scientific neurostimulation system for pain. Those who experience positive results from the trial may then receive a permanent implant of the neurostimulation system. The therapy will be personalized based on the investigators judgment and routine site care, following the studys inclusion and exclusion criteria. During the study, participants will be monitored as they receive neurostimulation therapy in real-world settings. Researchers will collect information on treatment outcomes and device performance over time. The study spans from 2012 to 2035, allowing for long-term observation of participants using these neurostimulation systems for pain relief.
Actively Recruiting
Researchers are evaluating whether Ultra Low Frequency ULF neuromodulation can reduce chronic nociceptive low back pain in adults and assessing its safety compared to conventional medical management CMM. This prospective, multi-center, randomized controlled trial focuses on adults with chronic, intractable axial low back pain with prominent nociceptive features, aiming to understand if ULF therapy offers better pain relief and any unexpected medical issues over 24 months. Participants will be randomly assigned in a 21 ratio to either receive ULF therapy combined with CMM or CMM alone. Those in the ULF group will first undergo a temporary trial phase and may receive a permanent implant if they experience at least 50% pain relief. At six months, participants can choose to switch to the other treatment if eligible. The primary outcome, back pain relief measured by a visual analog scale VAS, will be evaluated at three months with continued follow-up for a total of 24 months. During the study, participants will attend regular clinic visits for checkups and data collection. Researchers will assess pain levels, functional improvement, disability, opioid use, and quality of life using various tools including VAS and the Oswestry Disability Index ODI. Safety and treatment effects will be monitored over the entire two-year period to provide comprehensive information about ULF neuromodulation compared to standard care.